C25 BioTelemetry Inc.

BioTelemetry, Inc. Completes Acquisition of Geneva Healthcare, Inc.

BioTelemetry, Inc. Completes Acquisition of Geneva Healthcare, Inc.

MALVERN, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that the Company has completed its acquisition of Geneva Healthcare, Inc., the leading provider of remote monitoring for implantable cardiac devices.

Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “We are excited to welcome the Geneva team to BioTelemetry. This talented group of individuals has significantly transformed the way physician offices consolidate and manage data from implantable cardiac devices, giving precious time back to the staff to focus on patient care. Geneva’s market-leading platform and service, along with our scale and resources, make a formidable combination that will provide substantial benefits to the thousands of practices we serve. We look forward to working with the Geneva team to further solidify our leadership position in remote cardiac monitoring.

“Looking forward, for 2019 we expect Geneva to contribute at least $10 million of revenue with gross margin in excess of 60%. In the near term, our focus for Geneva will be on customer acquisition and top-line growth. As an early stage company, we will need to make investments in the business to support this goal. As such, we do not anticipate Geneva to be accretive to earnings in the first year post-acquisition.”

About BioTelemetry

BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care. We provide remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials and original equipment manufacturing that serves both healthcare and clinical research customers. More information can be found at .

Cautionary Statement Regarding Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements about both our beliefs and expectations regarding Geneva’s actual and expected annualized revenue and profitability and the growth and success of the combined entity. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises,” and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. For further details and a discussion of risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including the company’s latest periodic reports on Forms 10-K and 10-Q. Readers are cautioned not to put undue reliance on forward-looking statements, which reflect only opinions as of the date of this press release. 

We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Contact: BioTelemetry, Inc.

Heather C. Getz

Investor Relations

Executive Vice President, Chief Financial Officer

800-908-7103

EN
04/03/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioTelemetry Inc.

Heartbeam Inc: 1 director

A director at Heartbeam Inc sold 250,000 shares at 3.580USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

 PRESS RELEASE

Philips to Acquire BioTelemetry

Philips to Acquire BioTelemetry Philips to acquire BioTelemetry, Inc. for USD 72.00 per share; implied enterprise value of USD 2.8 billion (approx. EUR 2.3 billion)Acquisition is a strong fit with Philips’ strategy to transform the delivery of healthcare: combination of Philips’ leading patient monitoring position in the hospital with BioTelemetry’s leading cardiac diagnostics and monitoring position outside the hospitalWith 2019 sales of USD 439 million, BioTelemetry annually monitors over 1 million cardiac patients remotely; its portfolio includes wearable heart monitors, AI-based data an...

 PRESS RELEASE

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results Posts Record Quarterly Revenue Amidst Rapid Recovery MALVERN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended September 30, 2020. Quarter Highlights Recognized quarterly total revenue of $114.7 millionReached 3.0% year-over-year quarterly revenue growth, despite the impact of COVID-19Reported quarterly GAAP net...

MarketLine Department
  • MarketLine Department

CardioComm Solutions, Inc. - Mergers & Acquisitions (M&A), Partnership...

Summary Marketline's CardioComm Solutions, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by CardioComm Solutions, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdow...

 PRESS RELEASE

BioTelemetry, Inc. to Release Third Quarter 2020 Earnings Results on O...

BioTelemetry, Inc. to Release Third Quarter 2020 Earnings Results on October 29, 2020 MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on Thursday, October 29 at 4:00 PM Eastern Time. BioTelemetry, Inc. will host an earnings conference call on Thursday, October 29, at 5:00 PM Eastern Time.  The call will be webcast on the investor information page of our website, .  The call will be archived on our website for at least two weeks. About BioTelemetryBioTelemetry, Inc. is the leading remote medical technology comp...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch